Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1342

Sort by

Sort Order Select

Journal Articles

Retroperitoneal hemorrhage following a bone marrow biopsy

Krishna Gundabolu, Roberto Silva Aguiar

Blood (2021) 138 (14): 1283.

https://doi.org/10.1182/blood.2021011319

Published: 2021

Journal Articles

Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?

Juan Pablo Alderuccio, Derek Isrow, Isildinha M. Reis, Sunil Girish Iyer, Jessica J. Meshman, Wei Zhao, Francisco Vega, Jennifer R. Chapman, Arnold M. Markoe, Izidore S. Lossos

Blood (2020) 135 (15): 1299–1302.

https://doi.org/10.1182/blood.2019003236

Published: 2020

Includes: Supplemental data

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

Management Algorithms for Gaucher Disease Type 1 in Saudi Arabia: A Consensus Result from a National Meeting

Ayman Alhejazi, MD, Abdul Kareem Almomen, MD, Ahmad M Tarawah, Ahmed M AlSuliman, Hussain H. Al Saeed, MBBS, MD, Mahsen AlSaleh, MD, Ohoud F Kashari, Marwan Elbagoury, MSc, Omar Hussein

Blood (2019) 134 (Supplement_1): 4864.

https://doi.org/10.1182/blood-2019-122822

Published: 2019

Journal Articles

Retrospect Reviews of PNH Tests with Long-Term Follow-up in a Single Institution

Weiwei Wang, PhD, Gabrielle Meyers, MD, Haibo Li, Ying Wang, Lisong Shen, MD PhD, Guang Fan, MD PhD

Blood (2019) 134 (Supplement_1): 948.

https://doi.org/10.1182/blood-2019-124896

Published: 2019

Journal Articles

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Namrata S Chandhok, MD, Wei Wei, MD, Stephanie Halene, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 1374.

https://doi.org/10.1182/blood-2019-130033

Published: 2019

Journal Articles

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

Blood (2019) 134 (Supplement_1): 1532.

https://doi.org/10.1182/blood-2019-131442

Published: 2019

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

Blood (2019) 134 (Supplement_1): 555.

https://doi.org/10.1182/blood-2019-130046

Published: 2019

Journal Articles

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Hassan Awada, Reda Z. Mahfouz, MD PhD, Jibran Durrani, Ashwin Kishtagari, MBBS, Deepa Jagadeesh, MDMPH, Alan Lichtin, MD, Brian T. Hill, MD, Betty K. Hamilton, MD, Hetty E. Carraway, MD MBA, Navneet S. Majhail, MD MS, Ronald Sobecks, MD, Valeria Visconte, PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1226.

https://doi.org/10.1182/blood-2019-130167

Published: 2019

Journal Articles

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

Tomasz Knurowski, PhD MD, Karen Clegg, PhD, Nigel Brooks, PhD, Fay Ashby, Neil A Pegg, PhD, William West, PhD, Harriet S Walter, Tim CP Somervaille, MD PhD, Steven Knapper, DM, Andrew Davies, MD PhD

Blood (2019) 134 (Supplement_1): 1266.

https://doi.org/10.1182/blood-2019-124797

Published: 2019

Journal Articles

Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John Grainger, MD MRCP, FRPATH, James B. Bussel, MD, Michael D. Tarantino, MD, Nichola Cooper, Donald Beam, Jenny M. Despotovic, DO, Alexey A. Maschan, MD, Kejia Wang, PhD, Melissa Jeanne Eisen, MD, Charles Bowers, MD

Blood (2019) 134 (Supplement_1): 1095.

https://doi.org/10.1182/blood-2019-131241

Published: 2019

Journal Articles

Rationale for Targeting BCL6 in MLL-Rearranged B-ALL

Lai N Chan, PhD, Christian Hurtz, PhD, Huimin Geng, PhD, Erica Ballabio, Gang Xiao, PhD, Gauri Deb, MS, PhD, Haytham Khoury, MD PhD, Scott A. Armstrong, MD PhD, Patricia Ernst, PhD, Ari Melnick, MD, Tom Arthur Milne, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 1239.

https://doi.org/10.1182/blood-2019-131565

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

Jiasheng Wang, MD, Kirsten M Boughan, DO, Paolo F Caimi, MD, Brenda Cooper, MD, Marcos de Lima, MD, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Shufen Cao, Pingfu Fu, PhD, Benjamin Tomlinson, MD

Blood (2019) 134 (Supplement_1): 2607.

https://doi.org/10.1182/blood-2019-131293

Published: 2019

Journal Articles

Impact of Upfront Chemotherapy on Overall Survival in Isolated Myeloid Sarcoma

Konstantinos Lontos, MD, Jonathan G. Yabes, PhD, Michael Boyiadzis, MD

Blood (2019) 134 (Supplement_1): 2608.

https://doi.org/10.1182/blood-2019-123308

Published: 2019

Journal Articles

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Blood (2019) 134 (Supplement_1): 2638.

https://doi.org/10.1182/blood-2019-122120

Published: 2019

Journal Articles

Detailed Multi-Method Analysis of Bone Marrow from Pediatric Pre-B-ALL Patients Prior to CD19-CAR-T Therapy Subsequently Evidencing Overt CAR-T Resistance

Katherine Elizabeth Masih, BS, Rebecca Gardner, MD, Berkley Gryder, PhD, Abdelmaksoud Abdallah, BS, Justin Lack, PhD, Benjamin Stanton, PhD, Ashley Wilson, PhD, Sivasish Sindiri, MS, Young Song, PhD, Zachary Rae, BS, Michael Kelly, PhD, Wang Chaoyu, MS, Xinyu Wen, MS, Adam Cheuk, PhD, Jun Wei, PhD, Michael C. Jensen, MD, Javed Khan, MD, Rimas Orentas, PhD

Blood (2019) 134 (Supplement_1): 2744.

https://doi.org/10.1182/blood-2019-130796

Published: 2019

Journal Articles

Maximizing FDG-PET/CT Utility in Staging of Follicular Lymphoma (FL): The Role of Spleen Involvement and Bone Standardized Uptake Values

Frederique St-Pierre, MD, Stephen Broski, MD, Betsy Laplant, MS, Thomas M. Habermann, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 2811.

https://doi.org/10.1182/blood-2019-131992

Published: 2019

Journal Articles

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Kamal Menghrajani, MD, Sheng F Cai, MD PhD, Sean M. Devlin, PhD, Scott A. Armstrong, MD PhD, Richard Piekarz, MD PhD MS, BA, Michelle Rudek, PharmD, PhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 2655.

https://doi.org/10.1182/blood-2019-121926

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Retroperitoneal hemorrhage following a bone marrow biopsy

Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Management Algorithms for Gaucher Disease Type 1 in Saudi Arabia: A Consensus Result from a National Meeting

Retrospect Reviews of PNH Tests with Long-Term Follow-up in a Single Institution

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Rationale for Targeting BCL6 in MLL-Rearranged B-ALL

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

Impact of Upfront Chemotherapy on Overall Survival in Isolated Myeloid Sarcoma

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Detailed Multi-Method Analysis of Bone Marrow from Pediatric Pre-B-ALL Patients Prior to CD19-CAR-T Therapy Subsequently Evidencing Overt CAR-T Resistance

Maximizing FDG-PET/CT Utility in Staging of Follicular Lymphoma (FL): The Role of Spleen Involvement and Bone Standardized Uptake Values

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only